Last updated on: 9/24/2007 | Author:

Nathaniel Milton, PhD Biography

Clinical Neuroscience Researcher at London's Royal Free and University College Medical School
Not Clearly Pro or Con to the question "Should Marijuana Be a Medical Option?"

“I have shown that cannabinoids including noladin ether and anandamide are neuroprotective against amyloid-ß [chemical deposits in the brain].

The protective mechanism is mediated via cannabinoid CB1 receptor activation of p42/p44 kinase pathways [signaling pathways in the brain].”

Alzheimer’s Research Forum, Aug 28, 2006

Theoretical Expertise Ranking:
Individuals with MDs, PhDs, JDs, or equivalent advanced degrees in fields relevant to medical marijuana. Also top-level government officials (such as foreign leaders, US presidents, Founding Fathers, Supreme Court Justices, members of legislative bodies, cabinet members, military leaders, etc.) with positions relevant to medical marijuana issues.
Involvement and Affiliations:
  • Clinical Neuroscience Researcher, London’s Royal Free and University College Medical School
  • Co-founder and Research Director, NeuroDelta Ltd., 2003-present
  • Research Director, Insight Biotechnology Ltd., 1996-2004
  • Winner, University College London Entrepreneur’s Challenge competition, 2003
  • PhD, school unknown
  • None found